Singapore markets closed

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
40.61+0.93 (+2.34%)
At close: 04:00PM EDT
41.00 +0.39 (+0.96%)
After hours: 07:48PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.93B
Enterprise value 4.71B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.37
Price/book (mrq)18.48
Enterprise value/revenue 8.99
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.96
52-week change 3-53.27%
S&P500 52-week change 326.14%
52-week high 394.75
52-week low 319.83
50-day moving average 349.78
200-day moving average 352.19

Share statistics

Avg vol (3-month) 31.48M
Avg vol (10-day) 31.32M
Shares outstanding 5121.37M
Implied shares outstanding 6121.37M
Float 881.7M
% held by insiders 114.32%
% held by institutions 195.58%
Shares short (30 Apr 2024) 412.39M
Short ratio (30 Apr 2024) 48.46
Short % of float (30 Apr 2024) 414.12%
Short % of shares outstanding (30 Apr 2024) 410.21%
Shares short (prior month 28 Mar 2024) 410.44M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -79.62%
Operating margin (ttm)-36.03%

Management effectiveness

Return on assets (ttm)-27.90%
Return on equity (ttm)-122.94%

Income statement

Revenue (ttm)524.07M
Revenue per share (ttm)4.33
Quarterly revenue growth (yoy)284.30%
Gross profit (ttm)N/A
EBITDA -402.32M
Net income avi to common (ttm)-417.27M
Diluted EPS (ttm)-3.43
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)333.54M
Total cash per share (mrq)2.75
Total debt (mrq)109.14M
Total debt/equity (mrq)40.92%
Current ratio (mrq)3.77
Book value per share (mrq)2.20

Cash flow statement

Operating cash flow (ttm)-550.1M
Levered free cash flow (ttm)-383.48M